Citius Pharmaceuticals Inc
CTXR
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.54M
Close$
$0.22
58.5% downside
Current Fair Value
58.5% downsideOvervalued by 58.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.54 Million |
|---|---|
| Enterprise Value | $1.76 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.38 |
| Beta | 0.98 |
| Outstanding Shares | 22,376,427 |
Return
| Return on Equity | -88.16% |
|---|---|
| Return on Assets | -40.93% |
| Return on Invested Capital | -73.84% |
Valuation & Multiples
| P/E Ratio | -0.19 |
|---|---|
| PEG | -0.13 |
| Price to Sales | - |
| Price to Book Ratio | 0.18 |
| Enterprise Value to Revenue | 0.31 |
| Enterprise Value to EBIT | -0.03 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$10.23 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
$5.46 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 53,000▼ 60.80% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.46%▼ 3.55% |
|---|---|
| Total Invested | $896,918▼ 32.91% |
| Investors Holding | 40▼ 1.00% |
ESG Score
No data
About Citius Pharmaceuticals Inc
10 employees
CEO: Myron Holubiak